On the last Friday of the year, December 26, major U.S. indexes wrapped up the second straight week in record territory. Previously beaten down biotech names came back to life. Gilead Sciences temporarily recovered after the market corrected an overreaction to the termination of Gilead Science's agreement with Express Scripts. Earlier this week, the largest pharmacy-benefits manager in the U.S. dropped Gilead Sciences' hepatitis C drugs from its list of approved medicines. But some believe Gilead Sciences runs a strong operation regardless and could launch a large buyback program very soon. The company finished a couple percentage points higher. Gold also climbed a couple percentage points, its greatest gain in two weeks, pushing the $1,200 barrier. That is an important technical and psychological number to watch as we finish up the year -- gold finished at $1,206 in 2013.

More from Video

10 Seconds to Genius: Lowe's New CEO Marvin Ellison

10 Seconds to Genius: Lowe's New CEO Marvin Ellison

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

NYSE's New President: On a Mission to Attract Talent to Wall St.

NYSE's New President: On a Mission to Attract Talent to Wall St.

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

10 Seconds To Genius: Facebook

10 Seconds To Genius: Facebook